Danielle Ternyila

In an interview with Targeted Oncology, Andrea Price, APN, discussed the importance of integrating the electronic medical record team into the clinical care team for the treatment of patients with cancer receiving CAR T-cell therapy.

In an interview with Targeted Oncology, Yujin Hoshida, MD, PhD, discussed the next steps for improving upon the current understanding of hepatocellular carcinoma subtypes to improve responses and outcomes in patients.

"Accelerating the investigation of safe and effective therapies that could benefit people affected by the COVID-19 pandemic is one of the FDA’s highest priorities. We are committed to maximizing our regulatory flexibility and using every tool at our disposal to speed the development and availability of these medical products and believe these new guidance will help innovators and researchers do just that.”

In an interview with Targeted Oncology, Scott Haake, MD, discussed the current understandings of SETD2 mutations in clear cell renal cell carcinoma and the findings presented at the 2019 International Kidney Cancer Symposium.

“Our study demonstrates that venetoclax is a potential salvage therapy in multiply relapsed patients with MCL. The majority (92%) patients in this study were exposed to BTKi, 66% were BTKi refractory, and these patients exhibited poor outcomes."

“We’ve had to quickly shift gears and adapt to a new COVID-19 world. Our practices have taken every possible step to continue providing quality cancer care, safely. Because cancer does not stop for even a global pandemic, and neither does the need of cancer patients to get treated.”

"Current guidelines for the management of nausea and vomiting in patients with advanced cancer have not specifically indicated that one drug looks substantially better than a variety of other drugs. However, we believe the present results may be viewed as a best practice for treating nausea and vomiting in patients with advanced cancer-associated nausea and vomiting."

In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed the findings from the phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell RCC, which were presented at the 2020 Genitourinary Cancers Symposium.

Targeted Oncology reviews trending news online for the week of May 8, 2020, including recent updates from studies of COVID-19 and the latest oncology news.

To disseminate results that can inform the public health in response to COVID-19, CytoDyn announced the publication of their findings in a pre-print manuscript, which has been submitted for publication and is currently under peer review.

In an interview with Targeted Oncology, David Ritchie, MD, PhD, discussed the findings from the substudy of the AIM clinical trial, which evaluated the combination of venetoclax and ibrutinib in patients with MCL.

"This simultaneous therapy and companion diagnostic approval marks an important step forward in the treatment of rare cancer and demonstrates how deep collaboration across industry partners can advance patient care.”

In an interview with Targeted Oncology, Nikhil C. Munshi, MD, discussed the rationale for evaluating NKTR-255 as treatment of patients with multiple myeloma.

Based on these findings, the 200 mg dose of canakinumab administered subcutaneously every 3 weeks in combination with the standard dose of pembrolizumab and a platinum-based chemotherapy doublet will be used in the next phase of the CANOPY-1 study.

In an interview with Targeted Oncology, Lori A. Leslie, MD, discussed the importance of analyzing treatment outcomes in real-world patients with chronic lymphocytic leukemia compared with only reviewing data from clinical trials that do not represent all patients seen in the community setting.

“We are pleased that the FDA has approved Tabrecta for patients with METex14 NSCLC. Having a therapy that targets the recognized oncogenic driver will provide a much needed treatment option for patients with METex14 NSCLC who currently have limited treatment options.”

“To the best of our knowledge, this is the first report about obinutuzumab and venetoclax induced CR in a rituximab-intolerant patient with an ibrutinib-resistant leukemic MCL."

“While these findings cannot be exploited to improve clinical decision making today, our results, and the underlying data, collected on an increasingly rare group of triple-negative breast cancer patients treated with locoregional therapy alone, are a valuable contribution to ongoing research on the development, progression and ultimate treatment of triple-negative breast cancer."

"It’s extremely gratifying to see positive results for this important trial exploring the combination of umbralisib and ublituximab in patients with both front-line and relapsed/refractory CLL."

The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile.

“We are excited to partner with AON to continue to bring the same level of patient care and compassion coupled with access to additional services that will benefit our patients."

“This combined genomic and epigenomic plasma-based ctDNA test continues to demonstrate high sensitivity and specificity which significant implications for its clinical utility of CRC detection,”

In an interview with Targeted Oncology, Bruce L. Levine, PhD, discussed hot topics in the treatment landscape of melanoma, including the development of chimeric antigen receptor T and NK cells.

In an interview with Targeted Oncology, Michael A. Davies, MD, PhD, discussed the current treatment landscape of melanoma and the recent advances that have provided a great level of optimism to what has been known to be a very challenging cancer setting.

Targeted Oncology reviews trending news online for the week of May 1, 2020, including recent updates from studies of COVID-19 and the latest oncology news.

The electrical impedance spectroscopy system , Nevisense 3.0, a third-generation of the SciBase Nevisense system, for the early detection of melanoma has been granted FDA approval.

“We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing."

“The ATLANTIS trial reflects an exciting innovation in front-line precision cancer medicine for patients with advanced [urothelial cancer]."

In an interview with Targeted Oncology, Elizabeth M. Swisher, MD, discussed data for PARP inhibitor maintenance therapy in patients with ovarian cancer, including the VELIA study of veliparib and the ARIEL3 trial of rucaparib.

The FDA's Fast Track designation for second-line eryaspase as treatment of patients with metastatic pancreatic cancer underscores the need for new treatment options in this patient population.